|
 | | | | Introducing the MBC Advanced Mass Spectrometry Center at 1030 Brittan
We are excited to announce a new resource for high-quality, convenient, and accessible analytical support, sponsored by Agilent. Led by Dr. Yanan Yang, a mass spec expert with nearly two decades at Agilent, the center is equipped with the state-of-the-art Agilent 6495D QQQ and 6545XT QTOF systems. Researchers will have access to a wide range of services, from targeted omics and drug metabolism studies to peptide mapping, metabolomics, and impurity profiling. We offer end-to-end support, including consultation, sample prep, method development, data processing, and interpretation.
Service availability for both MBC residents and non-residents begins in early May. For questions, please contact yanan@mbcbiolabs.com. |
| | | | | Applications are now open for the 2025 Mission BioCapital Platinum Program
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
| | Montara Therapeutics adds $20M to seed fundraise for neurology pipeline
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
| | Nitrase Therapeutics Unveils Protein with Newly Characterized Enzymatic Function Involved in the Pathogenesis of Parkinson’s Disease
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
| | Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
| | TwoStep Therapeutics Unveils Its Lead Tumor-Targeted Drug Conjugate and New Radiopharmaceutical Program at Debut Scientific Presentation
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
| | | | Cooley Lunch Seminar - Navigating the Complexities of Product & Technology Licensing in a Global Market
April 9 @ 12 - 1pm 930 Brittan Ave, San Carlos
Join Cooley’s Life Sciences Partnering Group as they delve into the current landscape of biotech licensing deals. Drawing on recent deal experience, Lila Hope and senior members of Cooley’s Life Sciences team will deliver timely and relevant commentary on pharma activity and deal trends, and provide insight on transaction structures. Don’t miss this opportunity to gain a competitive edge and network with industry leaders in an interactive session.
REGISTER ► |
| WSGR Speaker Series & Happy Hour: IP/Patent Bootcamp for Biotech Companies
April 10 @ 3 - 5pm 135 Mississippi St, San Francisco
Join Wilson Sonsini & Goodrich for happy hour and an overview of IP topics, including patent strategies, trade secrets and freedom to operate studies.
REGISTER ► |
| Revvity Lunch & Learn: Cell & Gene Therapy
April 15 @ 12 - 1pm 135 Mississippi St, San Francisco
REGISTER ►
April 17 @ 12 - 1pm 930 Brittan Ave, San Carlos
REGISTER ►
Please join our partners at Revvity for an insightful lunch & learn session on the cutting-edge advancements of the Pin-point™ base editing platform, which can be utilized for sophisticated engineering tasks. |
| Founders at Work: Junevity
Cell Reset: siRNA Therapeutics for Longevity
April 16 @ 12 - 1pm 135 Mississippi St, San Francisco
Junevity is a biotechnology company developing cell reset therapeutics for longevity. The Junevity RESET platform is the first to use large-scale human data and AI to identify transcription factors for siRNA. Founded out of UCSF in 2023 based on Janine Sengstack’s PhD work in cellular aging, the company is creating siRNA therapeutics to address diseases impacting billions of people, including Type 2 diabetes, obesity, osteoarthritis and sarcopenia.
REGISTER ► |
| Cooley Lunch Seminar: Financing Trends in Life Sciences & Digital Health
April 22 @ 12 - 1pm 135 Mississippi St, San Francisco
Join Josh Seidenfeld, global chair of Cooley’s digital health group and a member of Cooley’s Life Sciences Advisory Board, for an insightful talk on the latest trends in the venture capital market. Josh will cover key market trends in the life sciences, digital health, and health technology spaces, where he is actively advising numerous clients on their raise. He will discuss significant investments and emerging opportunities in these sectors, providing actionable insights and data from Cooley’s extensive experience.
REGISTER ► |
| Women’s Health Innovation Forum
April 24 @ 1 - 5:30pm 1030 Brittan Ave, San Carlos
MBC BioLabs is hosting a Women’s Health Innovation Forum, bringing together a select group of pioneering startups, investors, and industry leaders to accelerate innovation in women’s and reproductive health. This exclusive gathering will spotlight early-stage companies developing diagnostics, therapeutics, and medical devices.
This event is invitation-only, but if you or someone in your network would be a strong fit, please reach out. We’re excited to foster high-quality connections that help early-stage companies gain traction in this critical space.
REGISTER ► |
| Founders at Work: Siren Biotechnologies
May 1 @ 12 - 1pm 135 Mississippi St, San Francisco
Siren Biotechnologies is combining the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single, powerful new treatment modality to fight cancer. Come hear about their experience transitioning from a Discovery to a Translational (& about to be Clinical) Stage company and what it's like to engage with the FDA right now.
REGISTER ►
|
| MBC BioLabs & MissionBio Capital Platinum Program Happy Hour
May 1 @ 5:30 - 7pm 930 Brittan Ave, San Carlos
Join us for a special Thirsty Thursday hosted by Mission BioCapital to learn about the Platinum Program. This initiative in collaboration with Eli Lilly, Ono Venture Investment, Alloy Therapeutics, HitGen, Goodwin, and van den Boom & Associates awards up to $500,000 per company for early-stage life sciences entrepreneurs. Enjoy a wine and cheese reception, learn about the program, and how to apply successfully. Stick around for tours of our newly opened facility just next door!
REGISTER ► |
|
|
|
|
|
|
|
|
|
|
| | | |  | Permanence Bio is developing small molecules that safeguard the genome from DNA damage caused by aging, radiation, and other mutagens. Our approach aims to prevent the onset of cancer and other age-related diseases by preserving genomic integrity.
A warm welcome to CEO Adam Tomusiak and Head of Chemoprevention Carlos Galicia to the 953 Indiana Street, San Francisco community!
READ MORE ► |
| | Cellentia uses patient-derived tumor organoids from dissociated tumor cells and from circulating tumor cells to enable highly translational preclinical drug screening, which we offer as a service and are establishing as an in-house discovery platform. Our ability to expand patient samples allows their use in a range of preclinical settings, including drug sensitivity, transcriptomics, and high-content imaging. Our unique ability to culture circulating tumor cells into tumor organoids enables drug developers to screen their drug candidates for efficacy against metastatic disease.
We are excited to welcome to CEO Shian Jiun Shih, Associate Director David Hsieh, Scientist Yi-chun Han, Project Manager Felix Hsieh, and Office Director Jessica Hsieh to the 930 Brittan Ave, San Carlos community!
READ MORE ► |
| | | | |
|
|
|
| |
|
